Table 1.
Patient, tumour, and treatment characteristics
| N | % | |
|---|---|---|
| Gender | ||
| Male | 17 | 85 |
| Female | 3 | 15 |
| Pathology | ||
| Squamous cell carcinoma | 20 | 100 |
| Tumour site | ||
| Oropharynx | 7 | 35 |
| Larynx | 8 | 40 |
| Hypopharynx | 5 | 25 |
| HPV status (Oropharynx) | ||
| Positive | 3 | 43 |
| Negative | 3 | 43 |
| Unknown | 1 | 14 |
| cT-Stage | ||
| T1 | 1 | 5 |
| T2 | 6 | 30 |
| T3 | 11 | 55 |
| T4 | 2 | 10 |
| cN-Stage | ||
| N0 | 9 | 45 |
| N1 | 3 | 15 |
| N2a | 1 | 5 |
| N2b | 7 | 35 |
| Stage grouping | ||
| Stage II | 2 | 10 |
| Stage III | 8 | 40 |
| Stage IV | 10 | 50 |
| Treatment | ||
| Radiotherapy | 6 | 30 |
| Cisplatin chemo-radiotherapy | 10 | 50 |
| Cetuximab-radiotherapy | 4 | 20 |
| [18F]HX4 PET imaging | ||
| Baseline | 20 | 100 |
| During RT | 17 | 85 |
| Radiotherapy dose between [18F]HX4 scans [Gy] | ||
| 18 | 3 | 18 |
| 20 | 5 | 29 |
| 22 | 6 | 35 |
| 24 | 2 | 12 |
| 26 | 1 | 6 |